CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease

Neurology

Volumn 50, Issue 1, 1998, Pages 169-174

  Tapiola, T ^a   Lehtovirta, M ^a   Ramberg, J ^a   Helisalmi, S ^a   Linnaranta, K ^a   Riekkinen Sr , P ^a   Soininen, H ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVE CELL DEGENERATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE DIAGNOSIS; REFERENCE VALUE; RISK FACTOR;

EID: 0031951155     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.1.169     Document Type: Article

References (37)

1. Lee VM, Baiin BJ, Otvos L Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991;251:675-678.
2. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 1975;72:1858-1862.
3. Kosik KS, Crandall JE, Mufson EJ, Neve EL. Tau in situ hybridization in normal and Alzheimer brain: localization in the somatodendritic compartment. Ann Neurol 1989;26:352-361.
4. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-652.
5. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease. Mol Chem Neuropathol 1995;26:231-245.
6. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995; 186:189-191.
7. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluid: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995;186: 181-183.
8. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
9. Munroe WA, Southwick PC, Chang L, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 1995;37:207-217.
10. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512-518.
11. Rosier N, Wichart I, Jellinger KA. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;60: 237-238.
12. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
13. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788793.
14. Vigo-Pelfrey C, Seubert P, Blomquist C, et al. Tau in cerebrospinal fluid: an antemortem marker for Alzheimer's disease. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer's disease and related disorders. New York: John Wiley & Sons, 1995:197-205.
15. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996;19:53-77.
16. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
17. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-530.
18. Nathan BP, Chang KG, Bellosta S, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995;270:19791-19799.
19. Huang DY, Goedert M, Jakes R, et al. Isoform-specific interac-tions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett 1994;182:55-58.
20. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125:163-171.
21. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-8102.
22. Wisniewski T, Golabek A, Matsubara E, et al. Apolipoprotein E: binding to soluble Alzheimer's beta- amyloid. Biochem Biophys Res Commun 1993;192:359-365.
23. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
24. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol (Berl) 1991;82:239-259.
25. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 1982;56:343-356.
26. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern hi Alzheimer's disease. Neurology 1992;42:1681-1688.
27. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
28. Trojanowski JQ, Clark CM, Arai H, et al. Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease. Alz Dis Rev 1996; 1:77-83.
29. Skoog I, VanMechelen E, Andreasson LA, et al. A populationbased study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 1995;4:433-442.
30. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
31. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
34. Heinonen O, Lehtovirta M, Soininen H, et al. Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Neurobiol Aging 1995;16:505-513..
35. Chin SS, Goldman, JE. Glial inclusions in CNS degenerative diseases. J Neuropath Exp Neurol 1996;55: 499-508.
36. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-282.
37. Mann DM, Yates PO, Marcyniuk B, Ravindra CR. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol 1986;12:447-457.